問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site > 收納受試者人數排名

Search Result

List

65Cases

2019-03-01 - 2020-12-31

Phase I

Clinical Pharmacology of LT5001 Drug Product in Hemodialysis Patients With Uremic Pruritus to Assess the Safety, Local Tolerance and Pharmacokinetics

  • Condition/Disease

    Hemodialysis Patients With Uremic Pruritu

  • Test Drug

    LT5001 drug product

Participate Sites
1Sites

Terminated1Sites

黃秋錦
China Medical University Hospital

Division of Nephrology

2014-03-01 - 2016-03-31

Phase II

An Open-Label, Dose-Finding, Phase II Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Paediatric Subjects aged 3 to 6 years and 2 to 35 months old

  • Condition/Disease

    Prevention of Enterovirus 71 infection

  • Test Drug

    EV71 vaccine

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

黃高彬
China Medical University Hospital

Division of Pediatrics

2015-12-01 - 2021-05-20

Phase I/II

A Phase 1b/2 Study of PEP503 (Radioenhancer) with Radiotherapy in Combination with Concurrent Chemotherapy for Patients with Head and Neck Cancer

  • Condition/Disease

    Head and Neck Cancer

  • Test Drug

    PEP503

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

趙坤山
China Medical University Hospital

Division of Hematology & Oncology

2013-04-16 - 2015-06-30

Phase III

A Phase III, randomised, observer-blind, placebocontrolled, multicentre study to assess the safety and immunogenicity of GSK Biologicals’ Herpes Zoster HZ/su candidate vaccine when administered intramuscularly on a two-dose schedule to adults aged 18 years and older with haematologic malignancies.

  • Condition/Disease

    Prevention of Herpes Zoster (HZ) and related complications in adults ≥50 years of age and immunocompromised adults ≥18 years of age. The current study will be performed in immunocompromised adults ≥18 years of age.

  • Test Drug

    gE/AS01B Vaccine

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2017-12-01 - 2018-12-20

Others

A Retrospective Chart Review Study of Patients Who Previously Participated in the PATRON Phase III Trial

  • Condition/Disease

    Adjuvant treatment of Post- Resection Hepatocellular Carcinoma

  • Test Drug

    Muparfostat (PI-88)

Participate Sites
10Sites

Terminated8Sites

Study ended1Sites

鄭隆賓
China Medical University Hospital

Division of Others-

2019-04-01 - 2022-12-31

Phase II

A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs)

  • Condition/Disease

    non-squamous non-small cell lung cancer

  • Test Drug

    Durvalumab、Tremelimumab

Participate Sites
8Sites

Recruiting8Sites

夏德椿
China Medical University Hospital

Division of General Internal Medicine

2018-11-01 - 2019-10-31

Phase III

A prospective, randomized, evaluator blind, active-controlled, parallel study of the efficacy and safety of Quiklean® and Klean-Prep with Dulcolax® for the bowel preparation prior to colonoscopy

  • Condition/Disease

    bowel preparation in subjects undergoing colonoscopy

  • Test Drug

    Quiklean

Participate Sites
2Sites

Terminated1Sites

Study ended1Sites

陳自諒
China Medical University Hospital

Division of Colorectal Surgery

2017-12-01 - 2020-12-31

Phase III

GRAVITAS-301： A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

  • Condition/Disease

    Acute Graft Versus Host Disease

  • Test Drug

    Itacitinib

Participate Sites
4Sites

Terminated3Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2014-12-01 - 2017-06-30

Phase III

A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT 1, GT 4 and GT 6 Infection in the Asia Pacific

  • Condition/Disease

    Chronic HCV GT 1, GT 4 and GT 6 Infection

  • Test Drug

    MK-5172A

Participate Sites
7Sites

Terminated6Sites

Study ended1Sites

彭成元
China Medical University Hospital

Digestive System Department

2017-05-10 - 2025-12-31

Phase III

A Phase III Randomized Double-blind Study of Pembrolizumab plus Best Supportive Care vs. Placebo plus Best Supportive Care as Second-Line Therapy in Asian Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-394)

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
4Sites

Terminated2Sites

Study ended1Sites

邱昌芳
China Medical University Hospital

Division of Hematology & Oncology

邱昌芳
China Medical University Hospital-Taipei

未分科

1 2 3 4 5 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB